Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.
-
Gan Q, Caraway NP, Ding C, Stewart JM. Primary Pancreatic Lymphoma Evaluated by Fine-Needle Aspiration. Am J Clin Pathol. 2022 Aug 04; 158(2):242-248.
-
Fisher KE, Ferguson LS, Coffey AM, Merritt BY, Curry JL, Marcogliese AN, Major AM, Kamdar KY, Lopez-Terrada DH, Curry CV. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance. Haematologica. 2022 Aug 01; 107(8):1880-1890.
-
Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 Jul 01; 107(7):1555-1566.
-
Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2757-2762.
-
Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Adv. 2022 05 10; 6(9):2745-2756.
-
Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2867-2871.
-
Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022 05 05; 139(18):2737-2746.
-
Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 07; 97(7):951-965.
-
Elfrink S, Ter Beest M, Janssen L, Baltissen MP, Jansen PWTC, Kenyon AN, Steen RM, de Windt D, Hagemann PM, Hess C, van Spronsen DJ, Hoevenaars B, van der Spek E, Xu-Monette ZY, Young KH, Kaffa C, Bervoets S, van Heek J, Hesius E, de Winde CM, Vermeulen M, van den Brand M, Scheijen B, van Spriel AB. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Adv. 2022 04 12; 6(7):2254-2266.